Since patients with immune‐favourable microenvironment and high tumour mutation burden benefited the most from immunotherapy especially immune checkpoint blockade therapy,29, 30 we further assessed the effect of SLC12A5 on immunotherapy response. Here, SLC12A5 is linked to neoplasm.